Benitec Biopharma (BNTC) Net Cash Flow (2019 - 2025)

Benitec Biopharma has reported Net Cash Flow for 7 years, with the latest figure at $94.5 million in Q4 2025.

• Quarterly Net Cash Flow rose 829.66% year-over-year to $94.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $110.7 million (up 92.17% YoY) and the FY2025 annual result came in at $46.9 million, down 3.27% from the prior year.
• Net Cash Flow rose to $94.5 million in Q4 2025 per BNTC's latest filing, from -$3.4 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $94.5 million in Q4 2025 and troughed at -$6.4 million in Q1 2024.
• A 5-year average of $8.7 million and a median of -$3.4 million in 2021 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow plunged 164.21% in 2022, then surged 1000.83% in 2024.
• Over 5 years, Net Cash Flow stood at -$3.3 million in 2021, then slumped by 77.42% to -$5.9 million in 2022, then advanced by 10.15% to -$5.3 million in 2023, then jumped by 293.25% to $10.2 million in 2024, then soared by 829.66% to $94.5 million in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered $94.5 million, -$3.4 million, and -$5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.